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Abstract
Since the discovery of HIV’s use of CCR5 as the primary coreceptor in fusion,
the focus on developing small-molecule receptor antagonists for inhibition hereof
has only resulted in one single drug, Maraviroc. We therefore investigated the
possibility of using small-molecule CCR5 agonists as HIV-1 fusion inhibitors. A
virus-free cell-based fusion reporter assay, based on mixing “effector cells”
(expressing HIV Env and luciferase activator) with “target cells” (expressing CD4,
CCR5 wild type or a selection of well-described mutations, and luciferase repor-
ter), was used as fusion readout. Receptor expression was evaluated by ELISA
and fluorescence microscopy. On CCR5 WT, Maraviroc and Aplaviroc inhibited
fusion with high potencies (EC50 values of 91 and 501 nM, respectively), whereas
removal of key residues for both antagonists (Glu283Ala) or Maraviroc alone
(Tyr251Ala) prevented fusion inhibition, establishing this assay as suitable for
screening of HIV entry inhibitors. Both ligands inhibited HIV fusion on signaling-
deficient CCR5 mutations (Tyr244Ala and Trp248Ala). Moreover, the steric hin-
drance CCR5 mutation (Gly286Phe) impaired fusion, presumably by a direct
hindrance of gp120 interaction. Finally, the efficacy switch mutation (Leu203Phe)
– converting small-molecule antagonists/inverse agonists to full agonists biased
toward G-protein activation – uncovered that also small-molecule agonists can
function as direct HIV-1 cell entry inhibitors. Importantly, no agonist-induced
receptor internalization was observed for this mutation. Our studies of the phar-
macodynamic requirements for HIV-1 fusion inhibitors highlight the possibility
of future development of biased ligands with selective targeting of the HIV–
CCR5 interaction without interfering with the normal functionality of CCR5.
Abbreviations
AIDS, acquired immunodeficiency syndrome; CCR5, C-C chemokine receptor type
5; CD4, cluster of differentiation 4; CXCR4, C-X-C chemokine receptor type 4;
ECL2, extracellular loop 2; gp120, glycoprotein 120; GPCR, G-protein-coupled
receptor; HAART, highly active antiretroviral therapy; HIV-1, human immunodefi-
ciency virus type 1; RLU, relative light units; TM, transmembrane domain; V3,
third variable loop; WT, wild type.
Introduction
Human immunodeficiency virus type 1 (HIV-1) belongs
to the Retroviridae family of single-stranded RNA viruses,
replicating through the process of reverse transcription.
The principal factors enabling entry of HIV-1 into a
human host cell are CD4 and a chemokine coreceptor, the
most important of which are CCR5 and CXCR4. These
two distinct chemokine receptors were originally discov-
ered in relation to their role as the primary coreceptors for
HIV-1 cell entry (Alkhatib et al. 1996; Bleul et al. 1996;
Deng et al. 1996; Feng et al. 1996; Oberlin et al. 1996),
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and have since been the targets of multitudes of anti-HIV
drug candidates (Steen et al. 2009; Chen et al. 2012). The
viral capsid of HIV-1, containing single-stranded RNA and
enzymes needed in the viral life cycle, enters the host cell
by fusion of the viral envelope with the cell membrane.
The fusion process is initiated by binding of the viral
envelope-associated glycoprotein 120 (gp120) to human
CD4, which facilitates secondary binding to a chemokine
coreceptor via exposure of the V3 loop (Biscone et al.
2006; Huang et al. 2007). During the early stages and
throughout most of the infection, HIV-1 typically exerts a
preference toward the use of CCR5 and is designated R5
tropic. The V3 loop proposedly binds to CCR5 in a two-
step fashion, not unlike the binding of endogenous
chemokines, the first step being recognition of the receptor
through interaction with the N-terminus and extracellular
loop 2 (ECL2) (Rucker et al. 1996; Huang et al. 2007;
Thiele and Rosenkilde 2014; Kufareva et al. 2015). Second,
interactions with residues in the TM domain are necessary
to permit the conformational changes of the viral envelope
protein required for entry into host cell (Garcia-Perez
et al. 2011a; Tamamis and Floudas 2014).
The current first-line treatment of HIV is a combina-
tion therapy (highly active antiretroviral therapy,
HAART) consisting of several antiretroviral drugs such as
nucleoside and non-nucleoside reverse transcriptase inhi-
bitors, protease inhibitors, and integrase inhibitors. These
all target essential viral enzymes in HIV’s replication
cycle; however, the high viral turnover and error-prone
nature of reverse transcription causes rapid mutation
(Wei et al. 1995; Preston et al. 1997), which eventually
leads to development of resistance (Werb et al. 2010;
Hughes and Andersson 2015). With recent changes in the
international treatment guidelines (WHO, 2015) in light
of the START study (Group et al. 2015) – suggesting start
of treatment at the time of diagnosis – there is an
increased risk of cumulative toxicity from the antiviral
drugs, and potential problems with adherence may fur-
thermore lead to increased prevalence of resistance (Babi-
ker et al. 2013). Targeting the human component, for
example, the chemokine fusion coreceptors, the develop-
ment of resistance is theoretically delayed, making such
drugs desirable anti-HIV agents. Aside from their core-
ceptor function in HIV/AIDS, the chemokine receptors
are involved in a number of physiological processes
including homeostasis and cell migration during develop-
ment and immune responses, as well as in the pathophys-
iology of autoimmune disease and cancer (Bachelerie
et al. 2014). Thus, targeting the human chemokine system
is not without risks, and roughly 20 years after the dis-
covery of HIV-1’s exploitation of chemokine receptors,
the attempts to create effective HIV-1 entry inhibitors
have only resulted in the approval of a single drug, the
CCR5 antagonist Maraviroc (FDA, 2007). Other drug
candidates, such as Aplaviroc and Vicriviroc, have failed
to complete clinical trial due to concerns about toxicity
and side effects resulting from off-site targets of these
antagonists (Nichols et al. 2008). Future development of
drugs that alone inhibit the interaction between HIV and
CCR5 and/or CXCR4 without interfering with the natural
chemokine-induced activity of the receptors (so-called
biased ligands with functional selectivity) are necessary to
avoid side effects caused by disruption of the chemokine
receptor function. The recently published crystal structure
of CCR5 (Tan et al. 2013) has helped improve the under-
standing of the interactions between the receptor and
gp120; however, this structure was of a Maraviroc-bound,
inactive conformation, and thus some limitations apply
to the model. Nonetheless, the key interaction points of
gp120–V3 have been found to be similar to those of Mar-
aviroc and Aplaviroc (Maeda et al. 2006; Kondru et al.
2008; Garcia-Perez et al. 2011a; Tan et al. 2013), suggest-
ing that the antagonists function through interference
with the secondary binding step. Furthermore, the inac-
tive Maraviroc-bound CCR5 conformation might also
play a role in the prevention of fusion (Garcia-Perez et al.
2011b; Tan et al. 2013).
In order to improve the knowledge needed for the
design of small-molecule ligands with functional selectiv-
ity toward HIV-1 fusion inhibition, we investigated the
conformational receptor requirements for HIV-1 interac-
tion using CCR5 as a model system. By utilizing previ-
ously well-described CCR5 mutations (Steen et al. 2013,
2014a,b), we applied inactive and constitutively active
receptor conformations in HIV-1 gp120-mediated fusion,
including some with bias toward G-protein activation and
absent b-arrestin recruitment. Furthermore, we studied
not only small-molecule receptor antagonists, but also
small-molecule agonists in the structural requirements of
HIV-1 inhibition by use of so-called efficacy switch muta-
tions in CCR5 (Steen et al. 2013, 2014b), where the
antagonist is converted to an agonist, which makes it pos-
sible to test whether small-molecule agonists are compa-
rable to antagonists in their ability to inhibit HIV-1
fusion. Mimicking infection of human cells with HIV-1, a
virus-free cell–cell fusion assay was utilized (Hong et al.
1999; Herschhorn et al. 2011) to highlight the potential
possibilities of designing improved CCR5-targeting drugs
for treatment of HIV-1.
Materials and Methods
Cell cultures and transfection
CHO-K1 cells were grown in 5% CO2 at 37°C in RPMI
1640 supplemented with 10% fetal bovine serum (FBS),
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2 mmol/L GlutaMAXTM (Gibco), 180 units/mL penicillin,
and 45 lg/mL streptomycin. Transfection of CHO-K1
cells was performed by lipofection using Lipofectamine
2000 (Invitrogen, Carlsbad, CA) as described previously
(Benned-Jensen and Rosenkilde 2010).
Plasmids
The human wild-type (WT) CCR5 cDNA was cloned
from a spleen-derived cDNA library into the expression
vector pcDNA3.1(+) (Invitrogen, Carlsbad, CA). Muta-
tions were constructed using QuikChangeTM site-directed
mutagenesis kit (Stratagene, La Jolla, CA) according to
the manufacturer’s instructions. All mutations were veri-
fied by DNA sequence analysis carried out by GATC Bio-
tech (Konstanz, Germany). CD4 was kindly supplied by
Mark Marsh (Cell Biology Unit, Medical Research Coun-
cil Laboratory for Molecular Cell Biology, University Col-
lege London, London, England). The CD4 construct was
transferred into the pcDNA3.1 Hygro(+) vector by PCR
cloning. DNA sequencing of CD4 revealed a N64I muta-
tion, which however had no influence on the fusion
capacity of CD4 and it was therefore used. The GAL4-
VP16 activator gene was generated by fusing the activa-
tion domain of the HSV1-encoded VP16 gene to the
GAL4 DNA-binding domain of Saccharomyces cerevisiae.
The GAL4-VP16 gene was synthesized and cloned into
the pUC57 vector by GenScript (Piscataway, NJ). The
gene was then transferred into the pcDNA3.1(+) vector.
The reading frame was confirmed by DNA sequencing.
Firefly luciferase reporter pGL4.31 was acquired from
Promega (Fitchburg, WI). R5-tropic HIV-1 Env (pJR-FL)
was kindly provided by Joseph Sodroski (Dana-Farber
Cancer Institute, Boston, Massachusetts, USA).
Ligands
The small-molecule antagonist Maraviroc was acquired
from Sigma-Aldrich. Aplaviroc was kindly provided by
Gary Bridger (AnorMED, Langley, British Columbia,
Canada). Both ligands were reconstituted at a stock con-
centration in DMSO, with a final assay DMSO concentra-
tion of less than 0.5%.
Cell–cell fusion assay
Subconfluent CHO-K1 cells were cotransfected with R5-
tropic HIV-1 Env and the GAL4-VP16 activator (“effector
cells”). Another CHO-K1 cell culture was cotransfected
with CD4, CCR5, and the pGL4.31 reporter (“target
cells”). One day after transfection, target cells were seeded
into 96-well plates (2 9 104 cells per well) and preincu-
bated with ligand in 100 lL of growth medium (w/o
added pen/strep) for 60 min. To initiate cell–cell fusion,
2 9 104 effector cells containing an equimolar ligand
concentration were overlaid for each well and coincubated
overnight. After coincubation, cells were washed, then
lysed, and assayed for luciferase activity with Steadylite
PlusTM (PerkinElmer Waltham, MA) according to the man-
ufacturer’s instructions, using a 2104 EnVision Multilabel
Reader (PerkinElmer, Waltham, MA). Luminescence regis-
tered as relative light units (RLU). Determinations were
made in triplicate.
ELISA
CHO-K1 cells were transfected with FLAG-tagged CCR5.
One day after transfection, the cells were seeded into 96-
well plates (4 9 104 cells per well) and incubated with
ligand in growth medium overnight. Cells were washed in
Tris-buffered saline (TBS) and then fixed with 3.7%
formaldehyde for 15 min at room temperature. After fixa-
tion, cells were washed and incubated in a blocking solu-
tion (TBS with 2% BSA) for 30 min. Cells were then
incubated for 2 h with anti-FLAG antibody (Sigma-
Aldrich) at 2 lg/mL in TBS with 1 mmol/L CaCl2 and
1% BSA. After washing with TBS/CaCl2/BSA, the cells
were incubated with goat anti-mouse HRP-conjugated
antibody (Abcam, Cambridge, UK) at a 1:1000 dilution.
Following additional washing, the immunoreactivity was
revealed by the addition of TMB Plus substrate (Kem-En-
Tec, Taastrup, Denmark), and the reaction was stopped
with 0.2 mol/L H2SO4 after 5 min. Absorbance was mea-
sured at 450 nm. Determinations were made in triplicate.
Calculations
Standard errors of the mean (SEM) were calculated from
row means and IC50 values were determined by nonlinear
regression using the GraphPad Prism 6.0 software
(GraphPad, San Diego, CA). P values were determined by
analysis of variance (ANOVA) using Dunnett’s multiple
comparison test with statistical significance defined as
P < 0.05.
Fluorescence microscopy
CHO-K1 cells were transfected with FLAG-tagged CCR5.
One day after transfection, the cells were seeded into 24-
well plates (5 9 104 cells per well) on fibronectin-coated
glass slides and incubated with ligand in 500 lL growth
medium overnight. Forty-eight hours post transfection,
the cells were fixed with 3.7% formaldehyde for 15 min.
To reduce unspecific staining, the cells were blocked in
2% BSA for 30 min and then permeabilized with 0.2%
saponin in PBS before incubation with the anti-FLAG-tag
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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antibody (M2) conjugated to Alexa Fluor 647 (10 lg/mL;
Cell Signaling) for 1 h at RT. The cells were washed three
times with PBS before the glass slides were mounted on
microscope slides, sealed, and visualized at 649 resolution
with oil using an Upright Laser Scanning Confocal
Microscope LSM700 (Zeiss).
Results
Effect of CCR5 alterations on baseline
gp120-mediated fusion
A selection of CCR5 mutations was made based on their
previously described phenotypes (Fig. 1A) with residue
positions designated in accordance to the Baldwin–
Schwartz/Ballesteros nomenclature (Baldwin 1993;
Schwartz et al. 1994; Ballesteros and Weinstein 1995),
including (1) inactive mutations (Y244A and W248A in
TM-6, position VI:09/6.44 and VI:13/6.48) (Steen et al.
2013), (2) constitutively active mutations (L203F in TM-5,
position V:13/5.47, G286F in TM-7, position VII:09/7.42,
and the double mutation L203F;G286F) (Steen et al. 2013,
2014b), two of which with lack of b-arrestin recruitment
(G286F and L203F;G286F), (3) a mutation with removed
small-molecule antagonist key anchor point (E283A in
TM-7, position VII:06/7.39) (Rosenkilde and Schwartz
2006; Thiele et al. 2011, 2012), and (4) a mutation with
removal of a residue suggested as an anchor point for Mar-
aviroc (Garcia-Perez et al. 2011a; Tan et al. 2013), but not
for Aplaviroc (Y251A in TM-6, position VI:16/6.51)
(Maeda et al. 2006; Kondru et al. 2008). To investigate the
effect of the mutations on the fusion process, effector cells
and target cells were mixed, and the level of fusion was
measured as firefly luciferase activity (Fig. 2A). The recep-
tor mutations were tested in parallel with WT CCR5 and
revealed markedly different levels of fusion (Fig. 2B and
Table 1). The luciferase activity for WT CCR5 was
matched only by L203F, while a decreased signal was
revealed for all of the remaining mutations with a ~50%
reduction for Y251A and E283A, followed by Y244A and
W248A at ~20–25% of WT level, and with the lowest level
of fusion for G286F together with the combined mutation
in L203F;G286F. The level of background activity was
found to be negligible (174  89 RLU).
Figure 1. Overview of mutations, ligands, and pharmacodynamic phenotypes included in current study. (A) Helical wheel structure of CCR5.
Mutated residues (white on black) marked with positions and phenotypes. Most conserved residue of every TM is indicated (black on gray). (B)
Chemical structure of the small-molecule antagonists Maraviroc and Aplaviroc.
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To ensure that the low level of fusion was not caused
by the absence of receptors, the surface expression of the
mutations was evaluated by ELISA against an N-terminal
FLAG-tag and compared to that of WT CCR5 (Fig. 2C
and Table 1). Two mutations matched the surface expres-
sion of WT CCR5 – L203F and E283A – while the
remaining mutations showed a lowered surface expression
level. The relationship between fusion signal and level of
receptor expression was further investigated by titrating
different amounts of WT CCR5 DNA during transfection
and measuring fusion (Fig. 2D). An increased signal was
observed in response to increasing amounts of receptor
DNA, indicating that cell–cell fusion was more prevalent
for target cells expressing larger amounts of CCR5. How-
ever, this relationship was not linear, likely due to the
nature of the cell–cell fusion assay, where only one
gp120–CCR5 connection in theory is necessary for
enabling fusion and thus luciferase production. Further-
more, we investigated how incubation time affected the
readout by incubating WT CCR5-expressing target cells
for 1 to 27 h (Fig. 2E). This revealed a highly time-
dependent reaction achieving a strong signal after 6 h
with lasting effect for the remainder of the tested incuba-
tion period (up to 27 h), which is comparable to previous
findings for the assay (Hong et al. 1999). A relatively high
background signal was observed immediately following
coincubation, but decreased with time, reaching its mini-
mum after approximately 10 h of incubation (Fig. 2E).
Consequently, overnight incubation was chosen for maxi-
mum specific window of fusion in the following studies.
The surface expression of all CCR5 mutations was suf-
ficient to allow fusion, which enabled testing of ligands
on these mutations, however due to its markedly
impaired fusion capabilities, G286F (and the combined
mutation L203F;G286F) was excluded from the following
studies of ligand interaction.
The fusion assay is sensitive to small
alterations in the ligand binding pocket
By employing the selected CCR5 mutations, we tested the
effectiveness of the small-molecule CCR5 antagonists,
Maraviroc and Aplaviroc (Fig. 1B), in the fusion assay.
We first focused on the key anchor point of most small
molecules targeting CC-chemokine receptors, Glu283 in
TM-7 (Rosenkilde and Schwartz 2006; Thiele et al. 2011,
2012). As expected, mutation to an alanine resulted in
loss of function for both Maraviroc and Aplaviroc
Figure 2. HIV fusion principle and properties of WT CCR5 and mutations. (A) Graphical presentation of the fusion assay principle. Mixing
effector cells expressing HIV-Env (gp120 + gp41) and luciferase activator with targets cells expressing CD4, CCR5, and luciferase reporter will
generate a luciferase readout proportionate to the degree successful cell fusion. (B) Baseline fusion, as measured by cell–cell fusion, of WT CCR5
and mutations shown in relative light units (RLU); n = 14–20. (C) Specific surface expression, as measured by ELISA, of WT CCR5 and mutations
shown as percentage of WT expression level; n = 6. (D) Change in fusion signal from transfection with different amounts of WT CCR5 DNA
shown in RLU, n = 3. (E) Change in fusion signal of WT CCR5 (black dots) and background signal (black squares) over time, representative data.
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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(Fig. 3A and B). Likewise, the Y251A mutation – a sug-
gested binding site for Maraviroc (Kondru et al. 2008;
Garcia-Perez et al. 2011a; Tan et al. 2013) – impaired
Maraviroc’s function (Fig. 3C). In contrast, this mutation
improved the potency of Aplaviroc (Fig. 3D and
Table 1).
The inactive CCR5 mutations Y244A and W248A
(Steen et al. 2013) revealed increased potency for both
ligands (Fig. 4A–D, and Table 1). Interestingly, when try-
ing to inhibit fusion for the W248A mutation with a high
concentration of either Maraviroc or Aplaviroc, the effect
was lost and instead an increase in cell–cell fusion was
observed. This was not a toxic effect, that is, causing
effector cell death and leakage of GAL4-VP16 to the med-
ium for uptake in target cells, as the same concentrations
did not increase the luciferase signal for any of the other
CCR5 mutations (Figs. 3 and 4). In order to investigate
the cause of this dose-dependent increase in fusion, we
investigated the impact of the two ligands on CCR5 sur-
face expression. In contrast to WT CCR5, where no note-
worthy increase in receptor surface expression was
observed (Fig. 5A), a moderate increase in expression was
observed for W248A at high ligand concentration
(Fig. 5E). This increase was surprisingly more pro-
nounced for the two other mutations in TM-6 (Y244A
and Y251A) (Fig. 5I and M), indicating that the increased
surface expression alone was not causing the increase in
fusion for W248A-CCR5. In contrast to the TM-6 muta-
tions, the surface expression of E283A (Fig. 5Q) was not
affected by ligand addition, which was to be expected
when removing the ligands’ key anchor point.
These observations were confirmed by fluorescence
microscopy (Fig. 5), shedding further light on the mecha-
nism behind the increased surface expression for Y244A,
W248A, and Y251A. Compared to WT CCR5 (Fig. 5B, C,
and D), intracellular stores were identified for these three
mutations (Fig. 5F, J, and N), which upon addition of
Maraviroc or Aplaviroc were transported to the cell sur-
face (Fig. 5G, H, K, L, O, and P). As expected, no visible
change was observed for WT CCR5 and E283A (Fig. 5B–
D and R–T).
The results on ligand interactions are in accordance
with the known roles of the selected residues, thus estab-
lishing that small-molecule ligands can be used in con-
junction with receptor mutations in this cell fusion assay.
Small-molecule agonists are efficient
inhibitors of R5-tropic cell–cell fusion
After having established that the cell–cell fusion assay is
sensitive to single amino acid alterations in CCR5 as well
as inhibition by the small-molecule antagonists, we next
wanted to study the effect of the efficacy switch mutationT
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on fusion. When inducing an efficacy switch of a ligand/
receptor pair, the effect of the ligand is reversed, that is,
an antagonist/inverse agonist becomes an agonist and vice
versa. Mutation of Leu203 in position V:13/5.47 to a
phenylalanine causes an increase in constitutive activity of
CCR5 through G proteins and thereby a shift toward an
active conformation that in turn leads to the efficacy
switch of Aplaviroc, which locks this active conformation
(Steen et al. 2014b). In addition to a surface expression
level close to that of WT CCR5, the functionality of
L203F in terms of affinity, efficacy, and potency of the
endogenous ligands, CCL3 and CCL5, is also similar to
WT CCR5 (Steen et al. 2014b), making it an ideal target
for the test. Furthermore, Aplaviroc works as a biased
agonist on L203F CCR5 as it is capable of stimulating
G-protein activity but not b-arrestin recruitment (Steen
et al. 2014b), thus providing insight into the direct inhi-
bitory effect of small-molecule agonists by preventing
b-arrestin-associated receptor internalization.
By targeting the efficacy switch mutation with Maravi-
roc and Aplaviroc, we investigated how small-molecule
agonists (biased toward G-protein activation) affect the
fusion process in the absence of agonist-induced receptor
internalization. Both Maraviroc and Aplaviroc displayed
potent inhibition of fusion on L203F (Fig. 6A and B),
closely matching the effect on WT CCR5. No decrease in
surface expression in response to increasing concentration
of ligand was observed (Fig. 6C and D), which was con-
firmed by fluorescence microscopy (Fig. 6E–H). This sug-
gests that a small-molecule agonist can work as an
effective, direct inhibitor of R5-tropic HIV-1 fusion, with-
out this effect being attributed to internalization of the
chemokine receptor.
Discussion
By studying receptor activity states and pharmacodynamic
requirements for fusion inhibitors, we here highlight the
possibility of development of functionally selective (i.e.,
biased) small-molecule ligands targeting the HIV–CCR5
interaction without interfering with the normal receptor
functionality. We used a cell–cell fusion assay as a tool
for investigation of the gp120 interaction, and through an
efficacy switch mutation in CCR5 we show that small-
molecule agonists function as effective inhibitors of HIV-1
fusion without decreasing receptor surface expression,
indicating no internalization and thus using another
mechanism (i.e., a more direct inhibition of the fusion
process) than described for the scarce existing small-
molecule agonists (Saita et al. 2006; Ferain et al. 2011).
Figure 3. Dose-dependent inhibition of cell–cell fusion by Maraviroc and Aplaviroc on WT CCR5 and anchor point mutations shown as
percentage of maximum fusion for each construct. Fusion inhibition on E283A (black circles) of (A) Maraviroc (n = 7) and (B) Aplaviroc (n = 6).
Fusion inhibition on Y251A (black triangles) of (C) Maraviroc (n = 8) and (D) Aplaviroc (n = 9). (A–D) Fusion inhibition on WT CCR5 (white
squares) with Maraviroc and Aplaviroc, both n = 10. (E) Helical wheel structure of CCR5 showing positions and phenotypes of the two mutations.
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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Sensitivity of the fusion assay and general
implications of the experiments
The observed potencies of Maraviroc and Aplaviroc on
WT CCR5 in the cell–cell fusion assay were comparatively
worse than initial studies have shown (Maeda et al. 2004;
Dorr et al. 2005). Since confluent cell seeding is required
to ensure membrane contact and only one gp120/CCR5
connection is required for cell fusion, inhibition of the
signal is potentially more difficult and requires higher
inhibitor concentrations, and thus has an inherent risk of
a right-shifted dose–inhibition curve, which explains this
discrepancy. This can also explain why the Y251A and
E283A mutations were able to support substantial fusion
despite their impairment in gp120 binding (Maeda et al.
2006). Nonetheless, we were able to confirm what has
been suggested for Maraviroc and Aplaviroc binding on
CCR5 as both inhibitors lose their effect upon removal of
the common Glu283 and specific Tyr251 anchor point
(Fig. 3). We observed an increase in potency of the inhi-
bitors for all TM-6 mutations (Table 1). Since we previ-
ously showed that the affinity of Aplaviroc is WT-like on
Figure 4. Dose-dependent inhibition of cell–cell fusion using Maraviroc and Aplaviroc on WT CCR5 and inactive mutations shown as percentage
of max fusion for each construct. Fusion inhibition on Y244A (black diamonds) of (A) Maraviroc (n = 9) and (B) Aplaviroc (n = 9). Fusion
inhibition on W248A (black hexagons) of (C) Maraviroc (n = 8) and (D) Aplaviroc (n = 8). (E) Helical wheel structure of CCR5 showing positions
and phenotypes of the two mutations.
Figure 5. Dose-dependent surface expression of WT CCR5 and mutations using Maraviroc and Aplaviroc. (A) ELISA for WT CCR5 with Maraviroc
(white squares) and Aplaviroc (black squares) shown as percentage of WT baseline, both n = 3. P = 0.003 for 10 lmol/L Maraviroc compared to
no ligand (**), and P = 0.447 for 10 lmol/L Aplaviroc compared to no ligand (not significant, n.s.). (B–D) Fluorescence microscopy of WT CCR5
without ligand, with 10 lmol/L Maraviroc, and with 10 lmol/L Aplaviroc, representative cells. (E) ELISA for inactive mutation W248A with
Maraviroc (white hexagons) and Aplaviroc (black hexagons) shown as percentage of WT baseline, both n = 3. P = 0.018 for 10 lmol/L Maraviroc
compared to no ligand (*), and P < 0.0001 for 10 lmol/L Aplaviroc compared to no ligand (****). (F–H). Fluorescence microscopy of W248A
without ligand, with 10 lmol/L Maraviroc, and with 10 lmol/L Aplaviroc, representative cells. (I) ELISA for inactive mutation Y244A with
Maraviroc (white diamonds) and Aplaviroc (black diamonds) shown as percentage of WT baseline, both n = 3. (J–L) Fluorescence microscopy on
Y244A without ligand, with 10 lmol/L Maraviroc, and with 10 lmol/L Aplaviroc, representative cells. (M) ELISA for anchor point mutation Y251A
with Maraviroc (white triangles) and Aplaviroc (black triangles) shown as percentage of WT baseline, both n = 3. (N–P) Fluorescence microscopy
of Y251A without ligand, with 10 lmol/L Maraviroc, and with 10 lmol/L Aplaviroc, representative experiment. (Q) ELISA for anchor point
mutation Y251A with Maraviroc (white circles) and Aplaviroc (black circles) shown as percentage of WT baseline, both n = 3. (R–T) Fluorescence
microscopy on E283A without ligand, with 10 lmol/L Maraviroc, and with 10 lmol/L Aplaviroc, representative experiment.
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W248A and Y251A (Steen et al. 2013), this increase in
potency can be explained by disrupted gp120 binding to
the receptor, and indeed impaired fusion was confirmed
for these three mutations (Fig. 2B and Table 1). Aside
from the increase in potency, a paradoxical increase in
cell fusion was observed for W248A at high ligand
(A) (B) (C) (D)
(F) (G) (H)
(J) (K) (L)
(N) (O) (P)
(R) (S) (T)
(E)
(I)
(M)
(Q)
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concentrations. This increase in cell fusion was accompa-
nied by a slight but significant increase in receptor surface
expression (Fig. 5E) resulting from mobilization of intra-
cellular receptor stores (Fig. 5F+G). A previous study
found that high Maraviroc concentrations increased WT
CCR5 expression after long incubation (>24 h) by
enhancing oligomerization of CCR5 on a synthesis level
(Nakano et al. 2014). Since the incubation time in our
experiment is shorter, thus insufficient to see a significant
effect of altered synthesis, and the increase in surface
expression of the mutations was seen at lower ligand con-
centrations as well, the explanation here is likely different.
The intracellular stores likely consist of “discarded” mis-
folded or otherwise defective receptors resulting from the
mutagenic manipulation. Mobilization of these stores to
the cell surface can be explained by the small molecules
entering the cells, binding to and somewhat stabilizing
the intracellular receptors allowing transport to the sur-
face, thus acting as molecular chaperones. Indeed, the
long incubation time makes cellular uptake or membrane
penetration of the small molecules a possibility. It is pos-
sible that this population of defective receptors has a
decreased affinity for the inhibitors while still supporting
gp120 binding, or allows for use of ligand bound recep-
tor, thus contributing to the observed biphasic inhibition
pattern. Similarly, a biphasic infectivity curve has been
described for another CCR5 antagonist, Vicriviroc, using
peripheral blood mononuclear cells and resistant HIV-1
strains (Anastassopoulou et al. 2009). A model based on
the existence of CCR5 subpopulations with varying affin-
ity for Vicriviroc was proposed as an explanation to this
phenomenon, which in essence is supported by a recent
study showing HIV’s exploitation of low-chemokine-affi-
nity G-protein-uncoupled CCR5 populations (Colin et al.
2013). This explanation fits with our observations for the
W248A mutation.
Of notice, the mutation suffering the biggest fusion
impairment, G286F comprising a steric hindrance, is
located in TM-7, pointing directly toward TM-6, indicat-
ing that the interface between TM-6 and TM-7 toward
the main binding pocket (Rosenkilde et al. 2010) is essen-
tial for gp120 interaction with CCR5 as suggested in pre-
vious studies (Garcia-Perez et al. 2011a; Tan et al. 2013;
Tamamis and Floudas 2014). It has previously been
shown that gp120 binding and HIV-1 infection are inde-
pendent of G-protein activation (Amara et al. 2003; Colin
et al. 2013), and our data support this notion. We tested
several CCR5 mutations with different activity states
(Steen et al. 2013, 2014b) and found no clear connection
between active/inactive conformations and gp120-
mediated fusion (Fig. 2B and Table 1), indicating that
HIV-1 entry inhibitors are not required to stabilize a cer-
tain conformation, thus improving the probability of suc-
cessful drug design.
(A) (B) (C) (D)
(E) (F) (G) (H)
Figure 6. Dose-dependent expression and inhibition of cell–cell fusion using Maraviroc and Aplaviroc on WT CCR5 and efficacy switch mutation.
(A, B) Fusion inhibition on efficacy switch mutation L203F (black circles) shown as percentage of own baseline, both n = 9. (C, D) ELISA for
efficacy switch mutation L203F (black circles) shown as percentage of WT baseline, both n = 3. P = 0.042 for 10 lmol/L Maraviroc compared to
no ligand (*), and P = 0.013 for 10 lmol/L Aplaviroc compared to no ligand (*). (E) Fluorescence microscopy of WT CCR5 without ligand,
representative experiment. (F–H) Fluorescence microscopy of efficacy switch mutation L203F without ligand, with 10 lmol/L Maraviroc, and with
10 lmol/L Aplaviroc, representative experiment.
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Improving drugs targeting CCR5 in HIV-1
fusion
Since the discovery of CCR5 and CXCR4’s role in HIV-1
infection, the focus has been on the development of
small-molecule entry inhibitors in the form of antagonists
(Steen et al. 2009; Chen et al. 2012), despite knowing that
peptide-based agonists such as the endogenous chemoki-
nes and modified versions of these also inhibit HIV-1
entry (Cocchi et al. 1995; Alkhatib et al. 1996; Bleul et al.
1996; Oberlin et al. 1996; Simmons et al. 1997). These
large peptides assert their effect through orthosteric
blockade of gp120, as well as the agonistic property of
b-arrestin recruitment leading to a reduction in corecep-
tors at the cell surface. More efficient variants hereof has
been designed (Simmons et al. 1997; Elsner et al. 2000);
however, due to the low bioavailability, short half-life,
and high production cost, these peptides were not suc-
cessful agents in the treatment of HIV. Thus, a small
molecule is preferable, however only a limited number of
such agonists with anti-HIV activity have been described
(Saita et al. 2006; Ferain et al. 2011), and their effect has
been solely attributed to internalization of CCR5. A valid
concern for such agonists is the possibility of proinflam-
matory side effects, resulting from activation of the classi-
cal signaling pathways, for example, Gai.
Lately, the concept of biased ligands has entered the
field of drug development, and G-protein-coupled recep-
tors (GPCRs) are obvious targets. For the treatment of
HIV, the theoretically most effective small-molecule ago-
nist would be biased toward b-arrestin recruitment and
receptor internalization, thus reducing receptor surface
expression without G-protein activation and thereby
diminishing the proinflammatory adverse effects associ-
ated with the Gai pathway. Reduction in cell surface
expression is a valid method for inhibition of HIV infec-
tion as proven by the fact that individuals carrying the
CCR5D32 mutation are resistant to HIV by reduced
CCR5 expression (Dean et al. 1996; Liu et al. 1996; Sam-
son et al. 1996; Ditzel et al. 1998). Targeting the human
component instead of viral proteins should in theory
decrease the risk of viral resistance development.
Nonetheless, resistance toward Maraviroc has been
described previously (Macarthur and Novak 2008; Flynn
et al. 2013). A biased drug as described above could con-
ceivably further reduce this risk as fewer drug-bound
receptors are exposed. Since it does not seem to be of
importance to the fusion process whether the blocking of
gp120 is induced by an antagonist or an agonist, we can
furthermore speculate on the possibility that a “silent”
drug (i.e., with no intrinsic effect on receptor signaling,
internalization, and chemokine binding) could have a
selective effect in HIV entry inhibition. This function
sparing probe-dependent allostery has in part been
described and discussed for the CCR5 antagonist TAK652
showing a more potent effect on HIV-1 entry inhibition
compared to inhibition of CCL3L1-induced CCR5 inter-
nalization (Muniz-Medina et al. 2009). Here, we show
effective fusion inhibition by small-molecule agonists with
no decrease in CCR5 surface expression, in accordance
with their lack of b-arrestin recruitment in L203F CCR5
(Steen et al. 2014b). This fits into the ideas that have pre-
viously been considered for small-molecule antagonists,
and adds the possibility of designing and introducing
biased or function sparing agonists as direct inhibitors of
HIV entry in treatment. Design of such a drug will pose a
novel strategy in combating the virus, and has the poten-
tial benefits of reducing the risk of drug resistance as well
as proinflammatory adverse effects otherwise associated
with chemokine receptor agonists. In light of the changes
in the HIV/AIDS treatment guidelines, suggesting an early
start of treatment, problems with resistance against the
traditional HAART regimen could potentially escalate,
providing the need for such new and improved drugs.
Even though toxicity will also increase when using multi-
ple drugs for an extended period of time, monotherapy is
currently not ideal in terms of antiviral activity. Thus, an
improved, functionally selective CCR5 ligand could prove
a rational supplement to the current treatment options.
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